Insulin Efsitora Alfa
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06362265 | Oct 2024 → Jan 2026 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06169982 | Dec 2023 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05914688 | Jun 2023 → Jan 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05596747 | Nov 2022 → Oct 2023 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05615532 | Nov 2022 → Jun 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04957914 | Jul 2021 → Oct 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04768842 | Mar → Sep 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04276428 | Feb → Nov 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03603704 | Aug 2018 → May 2019 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03367377 | Jan → Oct 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02942914 | Dec 2016 → Oct 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04450407 | Jul 2020 → Oct 2021 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04450394 | Jul 2020 → Oct 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03736785 | Nov 2018 → Feb 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05662332 | Jan 2023 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05463744 | Aug 2022 → May 2024 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05462756 | Aug 2022 → Feb 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05362058 | Jun 2022 → Apr 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05275400 | Mar 2022 → May 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin efsitora alfa | “This analysis aimed to assess the safety and tolerability of insulin efsitora alfa (efsitora, basal insulin Fc, LY3209590) and characterize the pharmacokinetic and...” PMID 39928225 ↗ Feb 20257“Basal insulin Fc (BIF, insulin efsitora alfa), designed for once-weekly administration, is a fusion protein combining a novel single-chain insulin variant with a human...” PMID 36758572 ↗ Feb 2023 “Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain” PMID 36944059 ↗ May 2023 |
| Known as | BIF | “Basal insulin Fc (BIF, insulin efsitora alfa), designed for once-weekly administration, is a fusion protein combining a novel single-chain insulin variant with a human...” PMID 36758572 ↗ Feb 20231“Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain” PMID 36944059 ↗ May 2023 |
| Known as | efsitora | “This analysis aimed to assess the safety and tolerability of insulin efsitora alfa (efsitora, basal insulin Fc, LY3209590) and characterize the pharmacokinetic and...” PMID 39928225 ↗ Feb 20254“Participants received 500 units per milliliter (U/mL) Insulin Efsitora Alfa (insulin efsitora) administered subcutaneously (SC) once weekly (QW) along with 100 U/mL insulin...” NCT05462756 ↗ “Plain Language Summary: Insulin efsitora alfa (efsitora) is an innovative once-weekly basal insulin treatment evaluated in the Phase 3 QWINT clinical trials.” PMID 41591636 ↗ Jan 2026 “The phase 3 QWINT-2 study demonstrated that once-weekly insulin efsitora alfa (efsitora) was noninferior to once-daily insulin degludec” PMID 42177728 ↗ May 2026 “Insulin efsitora alfa (efsitora) is a once-weekly basal insulin.” PMID 39270686 ↗ Sep 2024 |
| Known as | insulin efsitora | “Participants received 500 units per milliliter (U/mL) Insulin Efsitora Alfa (insulin efsitora) administered subcutaneously (SC) once weekly (QW) along with 100 U/mL insulin...” NCT05462756 ↗1“Participants received 500 units per milliliter (U/mL) Insulin Efsitora Alfa (insulin efsitora) administered subcutaneously (SC) once weekly (QW).” NCT05275400 ↗ |
| Known as | LY3209590 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05596747 ↗ |
| Modality | Protein / enzyme biologic | “is a fusion protein combining a novel single-chain insulin variant with a human immunoglobulin G (IgG) Fc domain.” PMID 36758572 ↗ Feb 2023 |
| Route | Subcutaneous | “LY3209590 administered subcutaneously (SC).” NCT02942914 ↗ |